A Phase 1/2 Study of YH001 in Combination With Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Doxorubicin (Primary) ; Envafolimab (Primary) ; YH 001 (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 19 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2023 According to Tracon Pharmaceuticals media release, Company expects to report trial data at the Connective Tissue Oncology Society (CTOS) annual meeting in November
- 10 May 2023 According to a TRACON Pharmaceuticals media release, data from this trial is expected in the second half of 2023.